Senses Disorder TRIZ Cases

Extracting postpartum-derived cells resolves the contradiction between cell source availability and purity while promoting cardiac tissue repair.

Inhibiting cathepsin S reduces complement activity and neovascularization, addressing the lack of effective dry AMD therapies.

Biodegradable polymeric nanoparticles enable sustained gene expression in the retina while avoiding immune responses associated with viral vectors.

Segmenting heterogeneous sulfated polysaccharides into structural categories enables precise activity profiling using mass spectrometry techniques.

AAV vectors deliver CLRN1 gene products to restore inner ear and retinal cell function, addressing permanent cellular damage from Usher syndrome.

Retro-inverso D-amino acid peptides resist proteolytic degradation to inhibit JNK signaling, addressing limited treatment options for cystitis.

A p75NTR binding protein captures neurotrophins to inhibit their functional activity.

Danazol modulates the endothelial cell cytoskeleton to inhibit vascular hyperpermeability, preventing tissue damage in diabetic retinopathy.

A platelet lysate composition transitions from liquid to gel to support corneal tissue structure and deliver growth factors.

ActRII antagonists block activin pathways to improve vision durability while avoiding complications from ischemia.

A bifunctional chimeric antibody binds hepatoma-derived growth factor and vascular endothelial growth factor to inhibit tumor proliferation.

Small molecule disaggregases restore lens flexibility by inhibiting alpha-crystallin aggregation, reversing presbyopia without invasive surgery.

Extended-release formulations reduce injection frequency and macular edema complications in wet AMD therapy.

6-Aminoisoquinoline compounds inhibit kinase activity to treat glaucoma and cancer.

Synergistic excipients maintain cobalamine stability at physiological pH, eliminating burning sensations while restoring tear saline content.

Formula I heteroaryl compounds inhibit PAD4 enzyme activity, resolving selectivity conflicts with PAD2 to reduce side effects in rheumatoid arthritis treatment.

A foam-forming composition releases hydrogen peroxide uniformly throughout body cavities upon application.

A pharmaceutical composition combining methylsulphonylmethane, glucosamine, and glycine reduces pro-inflammatory cytokines.

Ultracentrifugation isolates exosomes to promote corneal epithelial stem cell growth, avoiding rejection risks from whole-cell transplants.

Taiwanese propolis extract treats oxidative stress and hypoxia-induced damages in age-related macular degeneration and glaucoma models.

Heterocyclic compounds block SDF-1 binding to CXCR4 receptors to mobilize stem cells from bone marrow.

Topical KLK-13 binding antibodies enhance tear production by targeting the underlying pathogenic mechanism, addressing limitations of existing treatments.

Phospholipid and cholesterol formulations extend therapeutic agent retention in the vitreous humor, reducing intravitreal injection frequency.

Formula I compounds treat multi-drug resistant bacterial infections by targeting resistant pathogens with novel mechanisms.

Oxidatively transformed carotenoids enhance immunogenicity without adverse reactions, resolving the trade-off between vaccine safety and efficacy.

Tyrosine-to-phenylalanine mutations in AAV capsids evade ubiquitin-mediated degradation to enhance transduction efficiency in retinal bipolar cells.

Replacing hydrocarbon emollients with diethylhexyl carbonate reduces skin irritation and waste while maintaining microbead production quality.

Phenylpropanoid enhancers facilitate rapid drug transport through the buccal mucosa, resolving limited absorption rates in transdermal delivery.

PEDF-derived synthetic peptides accelerate wound healing by resolving the contradiction between cell expansion and spontaneous differentiation.

Modifying molecular structures to activate PPARδ improves metabolic stability and reduces kidney injury in muscular disease treatment.

Novel bivalent antibody format uses intra-chain disulfide bridges to stabilize variable domains and enhance tissue penetration.

Hydrated allyl isothiocyanate in a core-shell capsule stimulates reflex tearing without diluting natural tear components.

Novel formula I compounds inhibit blood coagulation factor IXa, reducing thrombus formation risk in patients with hypercoagulability.

Modified N-terminal linkers create stable alpha helical conformations, enabling targeted genomic cleavage at varying base pair separations.

Carboxyvinyl polymer, galactomannan, and borate stabilize nanoparticle suspensions to enhance nepafenac bioavailability despite corneal retention challenges.

Formula I compounds modulate Aiolos and Ikaros proteins to restore homeostasis, reducing inflammation and treating cancer.

Segmented hydroxymethyl ether hydroisoindoline structures provide effective neurokinin-1 receptor antagonism for treating central nervous system disorders.

Self-assembled flavonoid-polymer nanocomplexes encapsulate anti-VEGF drugs to enhance retinal accumulation and bioavailability.

QPI-1007 dsRNA targets Caspase 2 mRNA to reduce retinal ganglion cell death, addressing the lack of effective therapies for optic neuropathies like glaucoma.

Novel cycloalkane carboxylic acid derivatives inhibit CXCR3 receptors with high selectivity and oral bioavailability.

High penetration prodrugs convert retinoids to cross biological barriers via covalent linker modifications.

Deuterated diphenylaminopyrimidine compounds extend half-life via kinetic isotope effects, reducing neurological side effects from Fedratinib metabolites.

Sortilin antagonists interfere with pro-neurotrophin binding to prevent hair cell death and reverse hearing loss pathology.

Glycerol eye drops promote epithelial cell healing in Sjögren's syndrome by maintaining hydration without systemic side effects.

Selective CB2 receptor modulation treats inflammation and pain without triggering psychoactive effects.